VANCOUVER, British Columbia, Feb. 28, 2023 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company announces that effective at the opening of markets on March 3, 2023, the Class A Common Shares (the “Common Shares”) of the Company will commence trading following a four-for-one…


Previous articleBlossom – Making Psychedelic Education Accessible with David Drapkin from Psychedelics Today
Next articleOptimi Health Enters Australian Medical MDMA And Psilocybin Market With Mind Medicine Australia Distribution Agreement